Format
Sort by

Send to

Choose Destination

Search results

Items: 4

1.

Vaccinia Virus Shuffling: deVV5, a Novel Chimeric Poxvirus with Improved Oncolytic Potency.

Ricordel M, Foloppe J, Antoine D, Findeli A, Kempf J, Cordier P, Gerbaud A, Grellier B, Lusky M, Quemeneur E, Erbs P.

Cancers (Basel). 2018 Jul 10;10(7). pii: E231. doi: 10.3390/cancers10070231.

2.

Viral based vaccine TG4010 induces broadening of specific immune response and improves outcome in advanced NSCLC.

Tosch C, Bastien B, Barraud L, Grellier B, Nourtier V, Gantzer M, Limacher JM, Quemeneur E, Bendjama K, Préville X.

J Immunother Cancer. 2017 Sep 19;5(1):70. doi: 10.1186/s40425-017-0274-x.

3.

3D modeling and characterization of the human CD115 monoclonal antibody H27K15 epitope and design of a chimeric CD115 target.

Grellier B, Le Pogam F, Vitorino M, Starck JP, Geist M, Duong V, Haegel H, Menguy T, Bonnefoy JY, Marchand JB, Ancian P.

MAbs. 2014 Mar-Apr;6(2):533-46. doi: 10.4161/mabs.27736. Epub 2014 Jan 6.

4.

A unique anti-CD115 monoclonal antibody which inhibits osteolysis and skews human monocyte differentiation from M2-polarized macrophages toward dendritic cells.

Haegel H, Thioudellet C, Hallet R, Geist M, Menguy T, Le Pogam F, Marchand JB, Toh ML, Duong V, Calcei A, Settelen N, Preville X, Hennequi M, Grellier B, Ancian P, Rissanen J, Clayette P, Guillen C, Rooke R, Bonnefoy JY.

MAbs. 2013 Sep-Oct;5(5):736-47. doi: 10.4161/mabs.25743. Epub 2013 Jul 15.

Supplemental Content

Loading ...
Support Center